- Home
- YXT vs JSPR Comparison
YXT vs JSPR Comparison
Compare YXT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- JSPR
- Stock Information
- Founded
- YXT 2011
- JSPR 2018
- Country
- YXT China
- JSPR United States
- Employees
- YXT N/A
- JSPR N/A
- Industry
- YXT
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YXT
- JSPR Health Care
- Exchange
- YXT NYSE
- JSPR Nasdaq
- Market Cap
- YXT 102.1M
- JSPR 85.8M
- IPO Year
- YXT 2024
- JSPR N/A
- Fundamental
- Price
- YXT $0.99
- JSPR $4.14
- Analyst Decision
- YXT
- JSPR Strong Buy
- Analyst Count
- YXT 0
- JSPR 10
- Target Price
- YXT N/A
- JSPR $62.50
- AVG Volume (30 Days)
- YXT 77.3K
- JSPR 216.1K
- Earning Date
- YXT 03-27-2025
- JSPR 05-13-2025
- Dividend Yield
- YXT N/A
- JSPR N/A
- EPS Growth
- YXT N/A
- JSPR N/A
- EPS
- YXT N/A
- JSPR N/A
- Revenue
- YXT $45,374,087.00
- JSPR N/A
- Revenue This Year
- YXT N/A
- JSPR N/A
- Revenue Next Year
- YXT N/A
- JSPR N/A
- P/E Ratio
- YXT N/A
- JSPR N/A
- Revenue Growth
- YXT N/A
- JSPR N/A
- 52 Week Low
- YXT $0.83
- JSPR $4.11
- 52 Week High
- YXT $11.00
- JSPR $30.70
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- JSPR 26.71
- Support Level
- YXT N/A
- JSPR $5.11
- Resistance Level
- YXT N/A
- JSPR $5.53
- Average True Range (ATR)
- YXT 0.00
- JSPR 0.33
- MACD
- YXT 0.00
- JSPR -0.01
- Stochastic Oscillator
- YXT 0.00
- JSPR 1.87
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.